Patents by Inventor Moshe Talpaz
Moshe Talpaz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9868736Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB) by contact with a compound of formula (I).Type: GrantFiled: October 10, 2014Date of Patent: January 16, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Nicholas J. Donato, Moshe Talpaz, Luke Peterson, Matthew Young, Hollis D. Showalter, Christiane Wobus, Mary Xuan Dziem O'Riordan, Monika Ermann
-
Publication number: 20160237082Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB) by contact with a compound of formula (I)Type: ApplicationFiled: October 10, 2014Publication date: August 18, 2016Inventors: Nicholas J. Donato, Moshe Talpaz, Luke Peterson, Matthew Young, Hollis D. Showalter, Christiane Wobus, Mary Xuan Dziem O'Riordan, Monika Ermann
-
Patent number: 9096499Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.Type: GrantFiled: January 3, 2014Date of Patent: August 4, 2015Assignee: Board of Regents, The University of Texas SystemInventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
-
Publication number: 20140357673Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.Type: ApplicationFiled: July 31, 2014Publication date: December 4, 2014Inventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey William Perry, Roderick Joseph Sorenson, Mary Xuan Dziem O'Riordan, Yafei Jin
-
Publication number: 20140329901Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.Type: ApplicationFiled: January 3, 2014Publication date: November 6, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Waldemar PRIEBE, Nicholas DONATO, Moshe TALPAZ, Slawomir SZYMANSKI, Izabela FOKT, Alexander LEVITZKI
-
Patent number: 8809377Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g.Type: GrantFiled: September 23, 2011Date of Patent: August 19, 2014Assignee: The Regents of the University of MichiganInventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey W. Perry, Roderick J. Sorenson, Mary X. O'Riordan, Yafei Jin
-
Patent number: 8648102Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.Type: GrantFiled: January 13, 2012Date of Patent: February 11, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
-
Patent number: 8268837Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.Type: GrantFiled: November 22, 2005Date of Patent: September 18, 2012Assignees: Novartis AG, GSF, University of Texas SystemInventors: Nicholas J Donato, Doriano Fabbro, Paul W Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
-
Publication number: 20120214850Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.Type: ApplicationFiled: January 13, 2012Publication date: August 23, 2012Inventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
-
Publication number: 20120077806Abstract: Disclosed herein are methods of inhibiting a deubiquitinase (DUB), methods of treating pathogenic infections (e.g., viral, bacterial, and/or parasitic), methods of inhibiting cell proliferation, methods of treating a neurodegenerative disease, methods of treating one or more symptoms of a neurodegenerative disease or a genetic disorder, and compounds.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Nicholas J. Donato, Christiane Wobus, Hollis D. Showalter, Moshe Talpaz, Jeffrey W. Perry, Roderick J. Sorenson, Mary X. O'Riordan, Yafei Jin
-
Patent number: 8119827Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.Type: GrantFiled: June 28, 2010Date of Patent: February 21, 2012Assignee: Board of Regents, The University of Texas SystemInventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
-
Patent number: 8119649Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.Type: GrantFiled: May 14, 2009Date of Patent: February 21, 2012Assignees: Novartis AG, GSF-International Research Institute for Environment and Health, Board of Regents, The University of Texas systemInventors: Nicholas J Donato, Doriano Fabbro, Paul W Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
-
Publication number: 20110021805Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.Type: ApplicationFiled: June 28, 2010Publication date: January 27, 2011Applicant: The Board of Regents of the University of Texas SystemInventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
-
Publication number: 20100292229Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and/or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis.Type: ApplicationFiled: July 2, 2007Publication date: November 18, 2010Applicant: The Board of Regents of the University of Texas SystemInventors: Nicholas J Donato, David Maxwell, Moshe Talpaz, William Bornmann, Zhenghong PENG, Ashutosh Pal, Dongmei Han, Shimei Wang, Geoffrey Bartholomeusz, Vaibhav Kapuria
-
Patent number: 7745468Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.Type: GrantFiled: December 13, 2004Date of Patent: June 29, 2010Assignee: Board of Regents, University of Texas Systems TheInventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
-
Publication number: 20090227608Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.Type: ApplicationFiled: May 14, 2009Publication date: September 10, 2009Inventors: Nicholas J. Donato, Doriano Fabbro, Paul William Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
-
Patent number: 7468379Abstract: The present invention include methods and compositions for treating bone-resorbing diseases or bone resorption related to a pathologic condition generally, including, but not limited to osteoporosis, arthritis, rheumatoid arthritis, cancer metastases to the bone, bone cancer, hypercalcemia, osteolytic lesions with orthopedic implants, Paget's disease, and bone loss associated with hyperparathyroidism. Representative cancers include, but are not limited to breast cancer, prostrate cancer, colon cancer, endometrial cancer, multiple myeloma, renal cell carcinoma, heck and neck cancers, and cervical carcinoma. Arthritic conditions include, but are not limited to adjuvant-, collagen-, bacterial- and antigen-induced arthritis, particularly rheumatoid arthritis.Type: GrantFiled: June 16, 2006Date of Patent: December 23, 2008Assignee: The Board of Regents of the University of Texas SystemInventors: Bryant G. Darnay, Janet E. Price, Ann Poblenz, Moshe Talpaz
-
Publication number: 20070149539Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl }-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N- {5- [4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl }-4-(3-pyridyl)-2-pyrimidine-amine.Type: ApplicationFiled: February 28, 2007Publication date: June 28, 2007Inventors: Nicholas Donato, Doriano Fabbro, Paul Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
-
Publication number: 20070027167Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.Type: ApplicationFiled: September 5, 2006Publication date: February 1, 2007Inventors: Nicholas Donato, Doriano Fabbro, Paul Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
-
Publication number: 20070004748Abstract: The present invention include methods and compositions for treating bone-resorbing diseases or bone resorption related to a pathologic condition generally, including, but not limited to osteoporosis, arthritis, rheumatoid arthritis, cancer metastases to the bone, bone cancer, hypercalcemia, osteolytic lesions with orthopedic implants, Paget's disease, and bone loss associated with hyperparathyroidism. Representative cancers include, but are not limited to breast cancer, prostrate cancer, colon cancer, endometrial cancer, multiple myeloma, renal cell carcinoma, heck and neck cancers, and cervical carcinoma. Arthritic conditions include, but are not limited to adjuvant-, collagen-, bacterial- and antigen-induced arthritis, particularly rheumatoid arthritis.Type: ApplicationFiled: June 16, 2006Publication date: January 4, 2007Inventors: Bryant Darnay, Janet Price, Ann Poblenz, Moshe Talpaz